Three F.D.A. Advisers Resign Over Agency’s Approval of Alzheimer’s Drug: The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients

Three F.D.A. Advisers Resign Over Agency’s Approval of Alzheimer’s Drug: The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients: https://ift.tt/3zi3nIp Read more... https://ift.tt/2TjNmkL